ArticleJournal of nanobiotechnology2026
Neutrophil-guided pro-efferocytic mRNA platform for accelerated diabetic wound repair.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- De Novo Design Strategies of Nanomedicines for Diabetic Wound Microenvironment Remodeling.BME frontiers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe divergent fates of neutrophils play a critical yet complex role in tissue repair. However, how to harness the heterogeneity of neutrophil phenotypes in specific clinical contexts to guide the design of therapeutic materials remains poorly explored. In this study, inspired by the accumulation of apoptotic neutrophils (aNs) and exaggerated formation of neutrophil extracellular traps (NETs) in diabetic wounds, we innovatively developed nano-platform based on Interleukin 4 (IL-4) mRNA-enriched exosomes locally delivered by bisphosphonate (BP)-magnesium (Mg²⁺) coordination hydrogels.
resultsBeyond classical anti-inflammatory and glycolysis-modulating effects, we found that diabetic wound-specific accumulation of aNs surprisingly augmented the ability of our hydrogel to upregulate pro-repair genes. Moreover, the hydrogel formulations effectively rescued defective efferocytosis caused by excessive NETs, potentially through upregulating growth arrest specific 6 (Gas6) and myeloid-epithelial-reproductive tyrosine kinase (MerTK) expression. In vivo implantation of the composite hydrogels significantly accelerated the healing rate and improved the quality of skin wounds in diabetic mice.
conclusionIn summary, motivated by the divergent fates of neutrophils in diabetic wounds, we successfully engineered a pro-efferocytic platform based on IL-4 mRNA-primed exosomes incorporated into a coordination hydrogel, tailored specifically to promote diabetic wound repair.
Indexed as
Identifiers
42116131What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.